SRR23303758
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.400
- PEROXISOME+0.310
- SPERMATOGENESIS+0.240
- FATTY_ACID_METABOLISM+0.230
- PANCREAS_BETA_CELLS+0.170
- BILE_ACID_METABOLISM+0.150
- ADIPOGENESIS+0.110
- XENOBIOTIC_METABOLISM+0.110
- E2F_TARGETS+0.040
- CHOLESTEROL_HOMEOSTASIS+0.020
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.590
- INTERFERON_GAMMA_RESPONSE-0.540
- TNFA_SIGNALING_VIA_NFKB-0.500
- IL6_JAK_STAT3_SIGNALING-0.470
- ALLOGRAFT_REJECTION-0.460
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.430
- INFLAMMATORY_RESPONSE-0.410
- TGF_BETA_SIGNALING-0.410
- WNT_BETA_CATENIN_SIGNALING-0.390
- HYPOXIA-0.380
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-GV-A3JW-01A-11R-A20F-07 | — | — | 0.871 |
| 2 | TCGA-GU-A42P-01A-11R-A23W-07 | — | — | 0.870 |
| 3 | TCGA-E9-A1N3-01A-12R-A157-07 | — | B | 0.864 |
| 4 | 103802e1-b3a3-4c55-b094-5011798b6de3 | — | — | 0.862 |
| 5 | SRR12202427 | — | — | 0.857 |
| 6 | aMVAC.P_016_TURBT_S236 | — | — | 0.848 |
| 7 | AUR-AFE9-TTM1-A-1-1-R-A742-41 | — | B | 0.848 |
| 8 | SRR12202497 | — | — | 0.847 |
| 9 | SRR35579848 | — | B | 0.845 |
| 10 | TCGA-D8-A1XV-01A-11R-A14M-07 | — | B | 0.844 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.400 | Remibrutinib | — uncovered |
| PEROXISOME | 0.310 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.240 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.230 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.170 | Cobimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.150 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.110 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.110 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.040 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.020 | Remibrutinib | — uncovered |